You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Last Updated: December 3, 2023

CLINICAL TRIALS PROFILE FOR PERFLUTREN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Perflutren

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00398281 ↗	Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2006-11-01	RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
NCT00398281 ↗	Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer	Completed	Sidney Kimmel Cancer Center at Thomas Jefferson University	Phase 3	2006-11-01	RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
NCT00507806 ↗	Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke	Terminated	ImaRx Therapeutics	Phase 1/Phase 2	2005-03-01	The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity®]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Perflutren

Condition Name

Chart
Table

Condition Name for Perflutren
Intervention	Trials
Breast Cancer	3
Hepatocellular Carcinoma	3
Cystic Kidney Disease	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Perflutren
Intervention	Trials
Carcinoma	4
Breast Neoplasms	3
Carcinoma, Hepatocellular	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Perflutren

Trials by Country

Map
Table

Trials by Country for Perflutren
Location	Trials
United States	24
United Kingdom	3
Taiwan	1
India	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Perflutren
Location	Trials
Pennsylvania	8
California	5
North Carolina	4
Tennessee	2
Nebraska	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Perflutren

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Perflutren
Clinical Trial Phase	Trials
Phase 3	2
Phase 2/Phase 3	2
Phase 2	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Perflutren
Clinical Trial Phase	Trials
Completed	13
Recruiting	5
Not yet recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Perflutren

Sponsor Name

Chart
Table

Sponsor Name for Perflutren
Sponsor	Trials
National Cancer Institute (NCI)	6
Sidney Kimmel Cancer Center at Thomas Jefferson University	4
Thomas Jefferson University	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Perflutren
Sponsor	Trials
Other	30
NIH	10
Industry	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Merck

Johnson and Johnson

Boehringer Ingelheim

McKesson

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.